

BIOGEN IDEC INC  
Form 8-K  
April 10, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **April 4, 2006**

**Biogen Idec Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction  
of incorporation)

**0-19311**

(Commission  
File Number)

**33-0112644**

(I.R.S. Employer  
Identification No.)

**14 Cambridge Center, Cambridge, Massachusetts**

(Address of principal executive offices)

**02142**

(Zip Code)

Registrant's telephone number, including area code: **(617) 679-2000**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01 Entry into a Material Definitive Agreement**

**2006 Base Salary**

On April 4, 2006, the Compensation and Management Development Committee of the Registrant's Board of Directors approved an annual base salary of \$500,000 for Burt A. Adelman, MD, the Registrant's Executive Vice President, Development. The Committee also approved an annual salary of \$390,000 for Michael D. Kowolenko, Ph.D., the Registrant's Senior Vice President, Pharmaceutical Operations and Technology.

**Compensation Arrangement for the Chair of the Transaction Committee of the Board of Directors**

On April 5, 2006, the Registrant's Board of Directors approved a \$10,000 annual retainer to be paid to the Chair of the Transaction Committee of the Registrant's Board of Directors. The retainer is in addition to other compensation the Chair receives as a member of Registrant's Board of Directors.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Biogen Idec Inc.**

By: /s/ Susan H. Alexander  
Susan H. Alexander, Executive Vice  
President,  
General Counsel and Secretary

Date: April 10, 2006